U.S. markets open in 5 hours 34 minutes

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6700+0.0500 (+1.38%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close3.6200
Open3.6200
Bid0.0000 x 900
Ask0.0000 x 900
Day's Range3.6000 - 3.7000
52 Week Range2.8000 - 10.0000
Volume173,386
Avg. Volume304,987
Market Cap194.923M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-1.9380
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
    PR Newswire

    Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care

    Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists, today announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy & Rhinology, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatm

  • Optinose to Present at the Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Optinose to Present at the Jefferies Virtual Healthcare Conference

    YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event. About OptinoseOptinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn. Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com 267.521.0531

  • OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?